Hospital
HH Health System - Shoals LLC
HH Health System - Shoals LLC was paid $4.99M by Medicaid between Jan 2018 and Nov 2024, across 103 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoHH HEALTH SYSTEM - SHOALS LLC
SHEFFIELD, AL 35660
SHEFFIELD, AL 35660
33aNPI1508952235assigned 10/04/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.99M
24GClaims196,412
24DCodes billed103
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Alabama
Rank by total paid#13 of 77
Median peer was paid$1.13M
This provider vs. median4.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,158 | $522K | |
| 2019 | 33,277 | $514K | |
| 2020 | 19,725 | $346K | |
| 2021 | 32,274 | $670K | |
| 2022 | 28,751 | $1.03M | |
| 2023 | 25,363 | $1.33M | |
| 2024incomplete | 19,864 | $586K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 29,335 | 25,952 | $1.70M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 30% | 5,938 | 5,268 | $1.48M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 22,852 | 20,061 | $745K |
| 80053 | Comprehensive metabolic panel | 3.7% | 20,598 | 18,110 | $186K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.0% | 2,603 | 2,349 | $98K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.6% | 629 | 618 | $80K |
| 85027 | 1.3% | 18,642 | 16,535 | $67K | |
| 86710 | 1.3% | 4,929 | 4,352 | $66K | |
| 71045 | Radiologic examination, chest; single view | <1% | 10,184 | 9,149 | $48K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,763 | 4,067 | $44K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,243 | 3,731 | $42K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,971 | 2,614 | $40K |
91 more codes
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,596 | $33K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 3,732 | $31K |
| 81003 | <1% | 11,481 | $27K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 330 | $23K |
| 80081 | <1% | 344 | $20K | |
| G0378 | Hospital observation service, per hour | <1% | 504 | $19K |
| D9420 | <1% | 75 | $19K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 142 | $17K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 6,885 | $16K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,565 | $14K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 107 | $13K |
| 83690 | <1% | 2,153 | $12K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 30 | $12K |
| 81001 | <1% | 3,634 | $12K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 55 | $12K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 260 | $11K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,664 | $9K |
| 84703 | <1% | 1,616 | $8K | |
| 87807 | <1% | 689 | $7K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 303 | $6K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 294 | $5K |
| 87070 | <1% | 457 | $5K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 42 | $4K |
| 86787 | <1% | 258 | $4K | |
| 83605 | <1% | 445 | $4K | |
| 86803 | <1% | 252 | $4K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 260 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 265 | $4K |
| 84484 | <1% | 567 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 97 | $4K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 49 | $3K |
| 81025 | <1% | 871 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 242 | $2K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 33 | $2K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 378 | $2K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 56 | $1K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 146 | $1K |
| 83735 | <1% | 199 | $1K | |
| 80055 | <1% | 19 | $1K | |
| 82553 | <1% | 136 | $977.00 | |
| 82550 | <1% | 201 | $975.56 | |
| 87040 | <1% | 84 | $921.30 | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 28 | $902.29 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13 | $878.76 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,241 | $830.68 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 63 | $619.84 |
| 86780 | <1% | 31 | $615.84 | |
| 74018 | <1% | 72 | $535.26 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 933 | $515.03 |
| 85610 | <1% | 108 | $510.54 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 327 | $452.23 |
| 85014 | <1% | 179 | $447.63 | |
| 80061 | Lipid panel | <1% | 30 | $436.25 |
| 83525 | <1% | 46 | $404.40 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,571 | $381.88 |
| 59025 | Fetal non-stress test | <1% | 63 | $368.16 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 16 | $367.51 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 888 | $356.77 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 743 | $349.26 |
| 86765 | <1% | 30 | $300.84 | |
| 86592 | <1% | 64 | $290.88 | |
| 87081 | <1% | 41 | $267.00 | |
| 80076 | <1% | 43 | $264.96 | |
| 85730 | <1% | 91 | $227.15 | |
| 82607 | <1% | 12 | $226.08 | |
| 82105 | <1% | 12 | $225.10 | |
| 82950 | <1% | 30 | $197.96 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 68 | $192.96 |
| 85379 | <1% | 18 | $192.66 | |
| 82803 | <1% | 13 | $171.18 | |
| 86850 | <1% | 25 | $167.58 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,903 | $167.20 |
| 87186 | <1% | 13 | $120.15 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 12 | $107.76 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 81 | $76.12 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 14 | $67.20 |
| 86140 | <1% | 29 | $26.37 | |
| 86900 | <1% | 12 | $26.04 | |
| 86901 | <1% | 12 | $25.80 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 125 | $1.04 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 15 | $0.00 |
| 88312 | 0% | 47 | $0.00 | |
| 0353U | 0% | 13 | $0.00 | |
| 0240U | 0% | 554 | $0.00 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 364 | $0.00 |
| A9270 | Non-covered item or service | 0% | 5,149 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 813 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 160 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 26 | $0.00 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 0% | 42 | $0.00 |
| 96361 | Intravenous infusion, hydration; each additional hour | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBONETTI, VINCENT (EXECUTIVE DIRECTOR, REVENUE CYCLE)
| Provider | Location | Paid |
|---|---|---|
| H H Health System-Morgan LLC | Decatur, AL | $6.88M |
| HH Health System - Shoals LLC | Red Bay, AL | $176K |
| Medexpress Red Bay LLC | Red Bay, AL | $7K |
| Decatur General Hospital | Decatur, AL | $6K |
| Medexpress Littleville LLC | Russellville, AL | $5K |
| H H Health System-Morgan LLC | Decatur, AL | $328.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.